The kids won't necessarily get their meds. If Serepta is only reimbursed for their manufacturing costs and not for their administrative or research costs, they may not be in a position to provide this drug free of charge. The FDA has put them in a horribly untenable position: either they chose not to provide the drug and the kids die or they provide the drug and loose money with no hope of becoming a profitable company. Remember they don't have deep pockets like big pharma companies. The FDA has set them up to be the bad guys.
I'm OK with them paying more than they might have earlier if the extra time they took in evaluating their purchase leads to a better selection of what to purchase. The XTO purchase was a bad choice and now would be a good time to be more selective and not rush in to another bad choice.
In my view, for what it's worth, their next purchase will be for a company that has large oil/gas reserves since buying reserves is far less expensive and uncertain than drilling for them. Their need to replace reserves should be their top priority.
1. Exxon did use their AAA rating recently to borrow 12 billion dollars.
2. Exxon has 300 Billion dollars worth of treasury stock they have accumulated though their years of stock buybacks.
They are in a position to buy whatever company they see value in when ever they see fit to do so. It is not surprising they haven't bought yet. They will make sure what they buy will be beneficial to Exxon.